Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have to ask how me sending you a pic of myself will show you I am not Warp? Do you have a picture of Warp for the comparison? And if so, how did you obtain that? Or is Warp someone you personally know?
But I thought I was Warp. He's also accused me of being GMan and Maui. He's all over the map with those claims so I created a tool to him him out. You know, lessen the mental activity required. Help a brother out whose had Covid multiple times and experiences brain fog. Never even got a "thank you" for the effort I made.
I was planning to order myself a Dominos Pizza to celebrate his birthday, but decided to get a tuna sub instead.
Uh Oh!! Wasn't Warp on a sub in the service? Now that I mentioned a tuna sub, he will surely make the connection that proves I am Warp.
I had the option of getting a Tuna Wrap... but wait... rearrange Wrap and you get Warp. More proof. This is how brain fog works, folks. 😂
Todos Share Update - 9/29/23
75M shares issued since update on 9/22/23.
https://www.otcmarkets.com/stock/TOMDF/security
I'm still buying. I have faith share price will get sorted out by end of year to align better with true value of company. I'm taking the Novavax vaccine as soon as it's available to me.
Watching share price daily will drive you nuts. Invest here only if trading for quick in/out, otherwise hold longer term and ignore the short-term noise of wild share price swings.
Yeah, I own 2.2% of a company with real employees, real products producing real revenue. One of their products is now a key component in the treatment of Long Covid. What does MONI have? Empty promises. Bitgift product that never generated one dime of revenue, gold mines announced as acquired, then months later not really acquired, all-girl CEO and board with supposedly major Wall Street connections who suddenly were no longer there, and now using questionable individuals pumping the stock on social media. Credibility? LMAO
When someone is negotiating a purchase, unless they are an idiot, they NEVER state what they're willing to pay until AFTER the get the initial asking price from the seller. The seller may offer to sell for far lower than you're willing to offer, but if they hear your offer, their asking price automatically rises to match or counter with a slightly higher offer.
Apply this logic to purchasing shares of any stock. Why would someone announce how many shares they're preparing to buy and how much they're willing to pay for them, especially when the price is 5 to 10 times the current asking price for the shares. This person is either a MORON or is LYING. If someone wanted to buy that many shares, they would start accumulating now in smaller chunks. It may drive the price higher over time, but it's not going to be 5-10 times higher. Even if this intent was to buy after the merger/acquisition, it would be smart to start accumulating before the deal and get as many shares at the cheaper price, then BOOM, pick up the rest at the higher price point. This guy Borders is full of CRAP. Anyone not invested here and consumed by visions of riches can see it.
Sell and move on. Clearly you have zero hope for any recovery. Take your proceeds from the sale and buy yourself a McDonald's Happy Meal. Your life will improve immediately as you can focus on something other than your Todos losses. Life is too short to be this miserable.
Here are your choices. Let us know when you sell and which meal you choose. We are very interested. Really.
Heard from GC tonight. Todos corporate update will be Tuesday.
Todos Share Update - 9/22/23
75M shares issued since update on 9/15/23, following 6 weeks with no shares issued.
Corporate update coming on Monday.
The autumn equinox is tomorrow. Prediction of 3 billion shares and 0.0002/0.0003 bid/ask not reached. So now the big question... how far does the prediction get extended so as not to be proven wrong?
- - - - - - - - - -
a) Halloween
b) Thanksgiving
c) Winter equinox
d) Christmas Day
e) New Year's Day
f) April Fool's Day
"Ok, so my prediction of rain this week didn't happen. But, I expect it will rain next week or the following week, and certainly by end of next month. I am confident I will be proven right."
https://www.otcmarkets.com/stock/TOMDF/security
I'm surprised there wasn't a couple of dozen CONGRATULATIONS!!! in there somewhere. I guess he waits until he has the CEO and Board and Advisors all on the call to start kissing ass.
From his quotes he sounds like he thought of himself as one of GC's esteemed advisors. All those connections and he's still hasn't been able to score the big one in the penny stock world. And now blames the CEO when he's the one who brought the wolves to the lamb for slaughter.
Novavax: The Short Squeeze Story Isn't A Complete No-Brainer
Seeking Alpha
Sept 21, 2023
https://seekingalpha.com/article/4636569-novavax-the-short-squeeze-story-isnt-a-complete-no-brainer
There have been only 2 companies that achieved 100% recovery in hospitalized patients. One was Bioxytran, the other was Todos Medical with Tollovir. Both small companies dealing with convertible debt financing. Todos share price has been decimated by one of their lenders. Another lender is way underwater but holding on without converting. I guess we will have to wait and see what happens with the lending here. If phase 3 has similar results to phase 2 trial, share price will take off and I expect company will be acquired by big Pharma.
That's always a risk with convertible debt. Some players better than others. I don't know the history of Triton or whether they're a good or bad player in funding small caps. One would think with he success of the phase 2 trial a funder would want to help the company achieve a successful phase 3 trial and FDA approval, not start dumping shares to trigger conversions at lower and lower prices, but I've seen it happen many times with other companies. Death-spiral financing is the term.
I plan on buying more shares and holding through the phase 3 trials.
Bioxytran got the funding for Phase 3 trial.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172857671
Todos next with crowdfunding for NLC Pharma Tollovid/Tollovir trials.
NEWS: Bioxytran S-1 filing for Triton Funds investment to complete Phase 3 trial.
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317756483&type=PDF&symbol=BIXT&cdn=518eab6e3344025bc8b9759bf2fa0ace&companyName=Bioxytran+Inc&formType=S-1&formDescription=Registration+statement+under+Securities+Act+of+1933&dateFiled=2023-09-19
INSIDER FINANCIAL: The Next Axcella (AXLA) Squeeze >> Bioxytran (BIXT)
https://insiderfinancial.com/the-next-axcella-axla-squeeze-bioxytran-bixt/184558/
Made my first investment in Bioxytran this morning. Lots of potential here. Need to get Phase 3 testing funded and underway.
Yes, I believe they will find funding for phase 3, and made my first investment this morning. I intend to buy more.
I'm looking at it for an investment but haven't pulled the trigger yet.
Todos Share Update - 9/15/23
No shares issued since update on 8/4/23 - 6 weeks with no shares issued. I wonder what's going on at Todos... Tollovid and Provista Lab revenue improving?
Only 8 days until fall solstice/autumn equinox. Not looking good for predictions of 3 billion shares and 0.0002/0.0003 share price. Predictions will probably get updated to Halloween, Thanksgiving, Christmas, or New Years Day. Never to be proven wrong.
https://www.otcmarkets.com/stock/TOMDF/security
Thanks for the response. I picked up more NVAX today and buying more tomorrow. I'm taking the new vaccine as soon as it's available after FDA approval.
CEO on X (Twitter) - 9/10/23
CDC Announce New Effort to Combat Crisis of Sepsis in US Healthcare
Todos Share Update - 9/8/23
No shares issued since update on 8/4/23.
https://www.otcmarkets.com/stock/TOMDF/security
I picked up shares of Novavax this morning after the price tanked below $9 due to short sellers. The stock is highly shorted, which seems odd since they are close to getting FDA approval for their latest Covid vaccine. The earlier Novavax vaccine held up to mutations much better than their competitors. GC understands the mechanism of the various vaccines and speaks highly of Novavax vaccine. Huge short squeeze coming IMO so it was worth risking some cash to be in that game. Might even hold it long term if their fundamentals improve as expected.
Thanks for making me aware of the NVAX short status. In addition to buying shares, I will likely take the new vaccine once approved while I continue to take Tollovid daily. Regardless of what the U.S. media is reporting, the new variant seems to be pretty nasty based on X posts in the UK and Europe. Lots of folks who have it say it kicked their ass much worse than earlier variants. Since the U.S. stopped Covid testing, and many people here are against mask mandates and doing anything to contain the spread, we're probably looking at a tough winter ahead.
Keeping the faith with my Todos shares. Likely going to either fund NLC Pharma in their fundraising or pick up more Todos shares in the weeks ahead.
How high could this go during the short squeeze? Have you seen other stocks in this position regarding shorts? With such a high percentage of shares shorted, and with the new Covid vaccine relatively close to FDA approval, seems pretty risky to short this stock right now.
I took advantage of the sell-off/shorting today to buy shares under $9.
I think most have the jackass on ignore now as I don't see anyone responding. I believe he's still posting here because I see gaps in post numbering. What does that say about someone who posts when no one is reading your posts, yet they continue to do it? Oh yeah, the "save the newbie" movement. LMAO No newbie investor is going to even look at Todos unless the price starts moving up and they are highlighted on some of the services that flag big gainers. Then some newbie might try to take a position and ride the wave to make a quick buck. Any newbie who takes a longer-term position is likely going to online invest a few hundred they can afford to lose, unlike some who bet the bank on Amarantus and are still bitter a decade later, blaming the CEO and taking no responsibility themselves.
Funny, though, we don't see any posts trashing former IBIO CEO Thomas Isett. JP lost at least $20K there, probably more. But he had over six figures invested in Amarantus by his own posts here. I guess when one suffers catastrophic losses and financial ruin, scraping together another $20K to invest in another loser like IBIO is overshadowed by the former loss, so the attack on GC continues without pause and there isn't enough energy left to focus on trashing Isett.
The saving the newbie investor goal is certainly a worthwhile cause that has about 2 seconds of critical thought to put into it.
One piece of the Insider Financial article supports what some of us have been posting, that the delay in releasing updated financials is a strategic move to stop further conversions by the debt holder followed by dumping the converted shares on the market.
Todos Share Update - 9/1/23
No shares issued since update on 8/4/23.
https://www.otcmarkets.com/stock/TOMDF/security
Life is better when you can ignore the noise they make. Their only interest is to tear down the company and CEO and anyone still investing. I've had enough. Sad that some can't accept responsibility for their decision to invest even a decade later. Nothing useful comes from reading posts from those who use this board as a platform to grind their ax. Save newbies... my arse. 😂
Todos Medical – The Lotto Play with 10 to 1 Payout Challenges Pfizer’s Drug
INSIDER FINANCIAL
September 01 2023
The Covid stocks have gotten murdered and most are on life support or dead with the exception of Pfizer (NYSE: PFE). Todos Medical (OTCMKTS: TOMDF) is pretty much in the dead camp. It has 2.5 billion shares and was a dilution machine despite having a very credible business plan and good execution in spurts. The company has some amazing assets like the Videssa breast cancer test which is a blood test that can predict breast cancer before it is picked up on imaging. Over $50 million was put into that asset and about $10 million more gets it to the point of cash flow. They also have a very successful nutraceutical business that goes under the brand Tollovid. The website is up and they are still filling orders every day as people still desire immune protection from Covid even if they have to buy the dietary supplement.
The market cap of TOMDF is $1.7 million so it must be a good deal at $.0006 since it has an operating business, but when you look under the hood there is a mountain of debt. It’s so big that we aren’t going to give it a number. One of the largest noteholders is Levinston Resources and as the primary noteholder, they made many multiples of what they were owed and were arguably responsible for driving down the company’s price to a point that made them unfinanceable.
UNCOLLECTABLE NOTES
As the situation stands the note holders collectively have tons of debt they can never collect on unless they incentivize management to commercialize the assets. This is their only hope of repayment because their brokers won’t let them convert shares of an alternate reporting company. That means a deal has to be in the works and once the restructuring is complete the stock should surge as the noteholders will be incentivized to have the stock price move higher so the company can become fully operational again.
NOTE CONVERSION IMPOSSIBLE AT CURRENT PRICES
Investors that followed TOMDF closely might have noticed that $.008 was a staunch support level that once breached blew through 3 technical support levels to settle in at this $.0005 area. The reason for the breach and the dried up volume is that $.01 is the minimum level that certain stock brokers are allowed to deposit stock. Once the note holder deposited his last conversion the OTC investors noticed the increase in OS and pretty much went on strike and would buy any more stock. This created a perfect storm for the noteholder who eventually decided to liquidate what he had. Now the stock is so low he doesn’t have a prayer of depositing any more unless the price goes higher. The uptick in price and recent volume surge is a tell to investors that the noteholder is out of stock to sell.
In many social circles TOMDF is a four letter word because of the massive dilution that hit the market, but the reality is that future dilution cannot happen until $.01, and if the debt is squashed into equity it will be at a different price that works for the company and the noteholder. This means that at $.0005 the stock could run 10X+ before encountering any dilution resistance.
THE COVID CATALYST
As COVID ramps up this fall Tollovid sales are surely to increase as the cat is already out of the bag that they have a product that actually works in COVID and Long Covid according to their market research survey. If the company releases these COVID sales numbers with investors it’s going to give very good insight with respect to its future profitability. News that the company isn’t dead after all will give early investors at these lotto prices a very nice return.
THE PATENT NEWS
TOMDF just announced a Notice of Allowance for the composition of Tollovid and Tollovir. This patent news is as significant as the Axcella Therapeutics (NASDAQ: AXLA) patent news on Long Covid that moved the stock 300% higher. Todos has a lot of intellectual property related to their 3CL protease inhibitor.
INVESTMENT SUMMARY
Lotto plays are indeed risky but for this lotto plater there are too many viable assets within TOMDF to let it slip off into oblivion. A $5000 investment of stock could quickly multiply over the COVID season into something very significant. The recent momentum and buying has upticked the stock and shown alert investors that there isn’t a dilution overhang. It’s just a posting of buyers and sellers and if the stock continues to climb it will reach a point where the supply disappears and just moves higher on nothing. While it’s not known how long it will take to restructure the company and right size or eliminate the debt, the story of TOMDF is not ready for insolvency in at least the near future. TOMDF is a very educated lotto plat that could yield a healthy return for the patient investor.